Galapagos NV

Galapagos NV was founded in 1999 as a joint venture between Crucell and Tibotec. Its headquarters are located in Mechelen, Belgium, and it has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. As of December 31, 2022, Galapagos NV had a market capitalization of €5.8 billion.

Galapagos NV is focused on discovering, developing and commercializing innovative medicines for diseases with high unmet needs. It has a portfolio of programs ranging from discovery to Phase 4 in immunology, oncology and other indications. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Galapagos NV has received several awards for its achievements in the field of biotechnology. In 2019, it won the Scrip Award for Best Company in the EMEA Region. In 2020, it received the European Mediscience Award for Best Technology. In 2021, it was named one of the World's Most Innovative Companies by Fast Company.

Galapagos NV is also committed to advancing the science of cell therapy through its acquisitions of CellPoint and AboundBio in 2022. CellPoint is a leader in allogeneic CAR-T cell therapy for solid tumors. AboundBio is a pioneer in antibody-based gene delivery for rare diseases. These acquisitions will enable Galapagos NV to access next-generation cell therapies that have the potential to transform patients' lives.

Foundation: 1999

Headquarters: Mechelen, Belgium

Website: https://www.glpg.com/